Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Public ClinicalTrials.gov record NCT06655896. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
Study identification
- NCT ID
- NCT06655896
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 96 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 28, 2024
- Primary completion
- Nov 29, 2028
- Completion
- Aug 29, 2032
- Last update posted
- Aug 18, 2026
2024 – 2032
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA | Los Angeles | California | 90095 | Recruiting |
| UCSF | San Francisco | California | 94115 | Recruiting |
| Sutter Health Network | San Pablo | California | 94806 | Recruiting |
| FL Medical Clinic Orlando Health | Zephyrhills | Florida | 33542 | Recruiting |
| Northwestern University | Chicago | Illinois | 60611 | Recruiting |
| University Of Iowa | Iowa City | Iowa | 52242 | Recruiting |
| Boston Medical Center | Boston | Massachusetts | 02118 | Recruiting |
| Michigan Med University of Michigan | Ann Arbor | Michigan | 48109-5271 | Recruiting |
| University of Minnesota | Minneapolis | Minnesota | 55455 | Recruiting |
| James Cancer Hospital | Columbus | Ohio | 43210 | Recruiting |
| Oregon Health Sciences University | Portland | Oregon | 97239 | Recruiting |
| Avera Cancer | Sioux Falls | South Dakota | 57105 | Recruiting |
| LDS Hospital | Salt Lake City | Utah | 84143 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06655896, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06655896 live on ClinicalTrials.gov.